- Home
- MGTX vs SANA Comparison
MGTX vs SANA Comparison
Compare MGTX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- SANA
- Stock Information
- Founded
- MGTX 2015
- SANA 2018
- Country
- MGTX United States
- SANA United States
- Employees
- MGTX N/A
- SANA N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- SANA Medicinal Chemicals and Botanical Products
- Sector
- MGTX Health Care
- SANA Health Care
- Exchange
- MGTX Nasdaq
- SANA Nasdaq
- Market Cap
- MGTX 479.9M
- SANA 522.4M
- IPO Year
- MGTX N/A
- SANA 2021
- Fundamental
- Price
- MGTX $7.30
- SANA $3.01
- Analyst Decision
- MGTX Strong Buy
- SANA Strong Buy
- Analyst Count
- MGTX 2
- SANA 4
- Target Price
- MGTX $23.50
- SANA $13.00
- AVG Volume (30 Days)
- MGTX 278.8K
- SANA 3.3M
- Earning Date
- MGTX 03-13-2025
- SANA 03-07-2025
- Dividend Yield
- MGTX N/A
- SANA N/A
- EPS Growth
- MGTX N/A
- SANA N/A
- EPS
- MGTX N/A
- SANA N/A
- Revenue
- MGTX $13,929,000.00
- SANA N/A
- Revenue This Year
- MGTX N/A
- SANA N/A
- Revenue Next Year
- MGTX $1,391.84
- SANA N/A
- P/E Ratio
- MGTX N/A
- SANA N/A
- Revenue Growth
- MGTX 108.24
- SANA N/A
- 52 Week Low
- MGTX $3.85
- SANA $1.52
- 52 Week High
- MGTX $7.80
- SANA $12.00
- Technical
- Relative Strength Index (RSI)
- MGTX 66.58
- SANA 50.21
- Support Level
- MGTX $6.72
- SANA $3.00
- Resistance Level
- MGTX $7.06
- SANA $3.35
- Average True Range (ATR)
- MGTX 0.37
- SANA 0.24
- MACD
- MGTX 0.05
- SANA -0.03
- Stochastic Oscillator
- MGTX 71.61
- SANA 50.57
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.